These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37270761)

  • 1. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.
    Doub JB; Alkayali T; Amoroso A; Nandi S; Talwani R
    Eur J Orthop Surg Traumatol; 2023 Dec; 33(8):3655-3659. PubMed ID: 37270761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
    Wang Y; Wang J; Wang R; Li Y; Cai Y
    J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
    Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
    Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.
    Lange A; Thunberg U; Söderquist B
    BMC Infect Dis; 2023 Oct; 23(1):706. PubMed ID: 37858087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin in Gram-positive periprosthetic joint infections.
    Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
    J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Garnock-Jones KP
    Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin in clinical practice: a particular place for the elderly?
    Wackenheim C; Le Maréchal M; Pluchart H; Gavazzi G; Blanc M; Caspar Y; Pavese P;
    Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):977-979. PubMed ID: 35471751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study.
    Morata Ruiz L; Ruggieri A; Falcone M; Pasquau Liaño J; Gentile I; Salavert Lletí M; Moreno Núñez L; Cascio A; Tascini C; Loeches Yagüe M; De Rosa FG; Ori A; Comandini A; Cattaneo A; Grossi PA;
    J Glob Antimicrob Resist; 2024 Mar; 36():200-209. PubMed ID: 38211660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis on the safety of dalbavancin.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Ikuta I; Galindo M; Jordán J
    Expert Opin Drug Saf; 2021 Sep; 20(9):1095-1107. PubMed ID: 34042549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.